- Apomorphine Monotherapy for Parkinson’s Disease: A Neglected Option?
-
Clément Desjardins, Christelle Nilles, David Devos, Emmanuel Roze
-
J Mov Disord. 2023;16(3):328-330. Published online June 9, 2023
-
DOI: https://doi.org/10.14802/jmd.23057
-
-
2,778
View
-
118
Download
-
2
Web of Science
-
4
Crossref
-
PDF Supplementary Material
-
Citations
Citations to this article as recorded by 
- Simultaneous activation of different subtypes of dopamine receptors may lead to activation of homeostatic sleep regulatory mechanisms
Dóra Keserű, Tünde Hajnik, Máté Pethő, László Détári, Maarten Van Den Bossche, Attila Tóth Pharmacology Biochemistry and Behavior.2025; 248: 173954. CrossRef - Apomorphine: past, present and future in Parkinson’s disease and beyond
Manon Auffret Parkinsonism & Related Disorders.2025; : 107872. CrossRef - A Delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson’s disease and motor fluctuations.
Fabienne Ory Magne, Sophie Drapier, Ana-Raquel Marques, David Maltete, Frederique Leh, Cecile Hubsch, Frederique Fluchere, Margherita Fabbri, Angelique Gerdelat, Solene Frismand, Gwendoline Dupont, Cécile Delorme, Rene Decombe, Teodor Danaila, Jarbas Corr Parkinsonism & Related Disorders.2025; : 107866. CrossRef - Monotherapy with infusion therapies – useful or not?
Petra Bago Rožanković, Anders Johansson, Klivényi Péter, Ivan Milanov, Per Odin Journal of Neural Transmission.2024; 131(11): 1341. CrossRef
|